Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

IMRX

Immuneering Corp

Apr 19 • 04:00PM ET

1.80

Dollar change +0.03
Percentage change 1.69	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO CNCR IWC IWN VTWG AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.89	Insider Own	29.56%	Shs Outstand	29.27M	Perf Week	-14.29%
Market Cap	52.70M	Forward P/E	-	EPS next Y	-1.92	Insider Trans	-11.39%	Shs Float	20.63M	Perf Month	-35.25%
Income	-53.47M	PEG	-	EPS next Q	-0.50	Inst Own	38.49%	Short Float	13.94%	Perf Quarter	-69.54%
Sales	0.00M	P/S	-	EPS this Y	-0.36%	Inst Trans	-2.76%	Short Ratio	4.25	Perf Half Y	-70.00%
Book/sh	3.09	P/B	0.58	EPS next Y	-1.80%	ROA	-47.54%	Short Interest	2.88M	Perf Year	-86.08%
Cash/sh	2.93	P/C	0.62	EPS next 5Y	-	ROE	-53.36%	52W Range	1.75 - 14.29	Perf YTD	-75.51%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-57.97%	ROI	-56.44%	52W High	-87.40%	Beta	-0.64
Dividend TTM	-	Quick Ratio	11.35	Sales past 5Y	-43.59%	Gross Margin	-168734.95%	52W Low	2.86%	ATR (14)	0.32
Dividend Ex-Date	-	Current Ratio	11.35	EPS Y/Y TTM	1.47%	Oper. Margin	0.00%	RSI (14)	27.42	Volatility	10.87% 11.03%
Employees	68	Debt/Eq	0.05	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.75	Target Price	13.29
Option/Short	No / Yes	LT Debt/Eq	0.05	EPS Q/Q	-2.73%	Payout	-	Rel Volume	0.76	Prev Close	1.77
Sales Surprise	-	EPS Surprise	-12.34%	Sales Q/Q	-100.00%	Earnings	Mar 01 BMO	Avg Volume	676.02K	Price	1.80
SMA20	-21.04%	SMA50	-58.49%	SMA200	-73.55%	Trades		Volume	515,620	Change	1.69%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-24	Reiterated	Needham	Buy	$20 → $15
Mar-15-24	Downgrade	TD Cowen	Outperform → Market Perform
Mar-15-24	Downgrade	Jefferies	Buy → Hold	$16 → $3
Dec-01-23	Initiated	Needham	Buy	$20
Jun-26-23	Resumed	Oppenheimer	Outperform	$25
Apr-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$5 → $14
Apr-19-23	Upgrade	Mizuho	Neutral → Buy	$10 → $20
Mar-30-23	Initiated	Mizuho	Neutral	$10
Feb-03-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$12 → $5
Jul-08-22	Initiated	Chardan Capital Markets	Buy	$18
Apr-01-22	Initiated	Oppenheimer	Outperform	$25
Jan-07-22	Initiated	Piper Sandler	Overweight	$41

Show Previous Ratings

Apr-09-24 12:00PM	IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models (GlobeNewswire)
Apr-03-24 04:05PM	Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-24 08:00AM	Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire)
Mar-18-24 11:02AM	Immuneering (IMRX) Plummets 71% in One Week: Here's Why (Zacks) +34.03%
Mar-14-24 07:00AM	Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors (GlobeNewswire) -50.68%
08:00AM	Loading…
Mar-12-24 08:00AM	Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors (GlobeNewswire)
Mar-11-24 08:00AM	Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors (GlobeNewswire) -9.53%
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-05-24 05:00PM	Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-04-24 08:00AM	Immuneering to Participate in the Cowen 44th Annual Health Care Conference (GlobeNewswire)
Mar-03-24 07:01PM	Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
Mar-01-24 08:00AM	Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-20-24 08:00AM	Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer (GlobeNewswire)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +8.00%
Feb-01-24 08:00AM	Immuneering Announces Participation in February Investor Conferences (GlobeNewswire)
08:00AM	Loading…
Dec-12-23 08:00AM	Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire) -7.11%
Nov-20-23 04:05PM	Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-09-23 04:05PM	Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -11.86%
Oct-12-23 04:05PM	Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference (GlobeNewswire) -6.65%
Oct-04-23 04:05PM	Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-06-23 08:00AM	Immuneering to Present at the Morgan Stanley Healthcare Conference (GlobeNewswire)
Aug-03-23 04:05PM	Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-02-23 06:09AM	Immuneering Corporation (NASDAQ:IMRX) insiders have significant skin in the game with 28% ownership (Simply Wall St.)
Jul-05-23 09:55AM	Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet (Zacks)
Jun-05-23 08:00AM	Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors (GlobeNewswire)
May-30-23 08:00AM	Immuneering to Present at the Jefferies Healthcare Conference (GlobeNewswire) +6.86%
May-04-23 07:25PM	Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -8.75%
04:05PM	Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-18-23 09:24AM	Immuneering Announces $30 Million Underwritten Offering (GlobeNewswire) +9.60%
09:00AM	Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline (GlobeNewswire)
04:20AM	Loading…
04:20AM	Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last? (Zacks)
Apr-12-23 04:05PM	Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-11-23 03:56AM	Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains? (Zacks) +5.78%
Apr-05-23 08:00AM	Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-28-23 08:00AM	Immuneering Appoints Harold E. Brakewood as Chief Business Officer (GlobeNewswire) -7.40%
Mar-27-23 09:55AM	Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade (Zacks)
Mar-24-23 01:25PM	Why Shares of Immuneering Jumped This Week (Motley Fool)
Mar-23-23 06:18AM	Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock? (Zacks)
Mar-14-23 04:30PM	Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire) +5.62%
Mar-09-23 09:55AM	Does Immuneering Corporation (IMRX) Have the Potential to Rally 210.19% as Wall Street Analysts Expect? (Zacks) +5.47%
Mar-08-23 07:14AM	Immuneering Corporation (NASDAQ:IMRX) Q4 2022 Earnings Call Transcript (Insider Monkey) +22.87%
Mar-06-23 05:45PM	Immuneering Corporation (IMRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-23 06:30PM	Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity (GlobeNewswire)
Feb-28-23 08:00AM	Immuneering Announces Participation in March Investor Conferences (GlobeNewswire)
Feb-27-23 08:00AM	Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates (GlobeNewswire)
Feb-05-23 07:18AM	Immuneering Corporation (NASDAQ:IMRX) insiders, who hold 31% of the firm would be disappointed by the recent pullback (Simply Wall St.)
Jan-31-23 06:50AM	Immuneering To Present at Guggenheim 2023 Oncology Conference (GlobeNewswire)
Nov-28-22 06:50AM	Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (GlobeNewswire)
Nov-16-22 06:35AM	Immuneering Third Quarter 2022 Earnings: Revenues Disappoint (Simply Wall St.)
Nov-10-22 10:15AM	Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
09:00AM	Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
09:00AM	Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC (GlobeNewswire)
Nov-03-22 06:50AM	Immuneering Announces Participation in November Investor Conferences (GlobeNewswire) -12.80%
Oct-20-22 06:50AM	Immuneering Appoints Leah R. Neufeld as Chief People Officer (GlobeNewswire)
Oct-05-22 08:05AM	Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) -5.80%
Sep-30-22 12:00PM	What Makes Immuneering Corporation (IMRX) a New Buy Stock (Zacks) +9.15%
06:50AM	Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations (GlobeNewswire)
Sep-12-22 09:55AM	Wall Street Analysts See a 148% Upside in Immuneering Corporation (IMRX): Can the Stock Really Move This High? (Zacks) +10.82%
Sep-05-22 10:21AM	Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104 (Zacks)
Sep-02-22 08:09AM	Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations (GlobeNewswire) +7.05%
Aug-25-22 09:55AM	Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 224%: Here's is How to Trade (Zacks) -7.35%
06:50AM	Immuneering Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-10-22 05:55PM	Immuneering Corporation (IMRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-08-22 12:24PM	Immuneering (NASDAQ:IMRX) shareholders have endured a 77% loss from investing in the stock a year ago (Simply Wall St.) +11.25%
Jul-22-22 10:01AM	Lumos (LUMO) Soars 9.4%: Is Further Upside Left in the Stock? (Zacks)
Jul-11-22 07:57AM	What Type Of Shareholders Own The Most Number of Immuneering Corporation (NASDAQ:IMRX) Shares? (Simply Wall St.)
Jul-08-22 11:40AM	Why This Small-Cap Stock Is Gaining More Than 10% Today? (Benzinga) +28.85%
Jul-06-22 06:50AM	Immuneering Announces Participation in William Blair Biotech Focus Conference 2022 (GlobeNewswire) +5.80%
May-26-22 05:26PM	Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104 (GlobeNewswire) +11.31%
May-20-22 06:50AM	Immuneering Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-10-22 06:30AM	Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) +13.99%
May-09-22 08:54AM	Immuneering Corporation (NASDAQ:IMRX) insiders placed bullish bets worth US$10.0m in the last 12 months (Simply Wall St.) -12.63%
May-05-22 06:50AM	Immuneering Announces Participation in Citis Biopharma VIRTUAL Co-Panel Day (GlobeNewswire) -8.36%
Apr-07-22 10:46AM	Oppenheimer Sees Gains of Over 100% in These 3 Beaten-Down Stocks (TipRanks) +5.09%
Apr-01-22 06:50AM	Immuneering Announces Participation in Piper Sandler AI/ML Investor Conference (GlobeNewswire) +14.99%
Mar-24-22 06:55AM	Immuneering Announces Participation in the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-10-22 08:46AM	Is a Surprise Coming for Immuneering (IMRX) This Earnings Season? (Zacks)
06:30AM	Immuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-24-22 06:50AM	Immuneering Announces Participation in March Investor Conferences (GlobeNewswire) +5.46%
Feb-07-22 08:30AM	Should You Buy Immuneering (IMRX) Ahead of Earnings? (Zacks)
Jan-31-22 12:24PM	What Is The Ownership Structure Like For Immuneering Corporation (NASDAQ:IMRX)? (Simply Wall St.)
Jan-24-22 06:50AM	Immuneering Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-19-22 08:00AM	PepGen Appoints Laurie Keating as Chair of Board of Directors (GlobeNewswire)
Jan-18-22 06:50AM	Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D. (GlobeNewswire)
Jan-06-22 04:10PM	Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External Expert Investor Event (GlobeNewswire) -8.66%
Jan-03-22 06:50AM	Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management (GlobeNewswire) +5.07%
Dec-16-21 06:50AM	Immuneering Added to the Nasdaq Biotechnology Index (GlobeNewswire)
Nov-18-21 06:35AM	Immuneering Announces Participation in December Investor Conferences (GlobeNewswire)
Nov-10-21 06:50AM	Immuneering to Participate in Jefferies 2021 London Healthcare Conference (GlobeNewswire)
Nov-09-21 06:30AM	Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-01-21 09:20AM	Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth (Simply Wall St.)
Oct-11-21 06:50AM	Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) -18.44%
Oct-01-21 06:50AM	Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +8.85%
Sep-20-21 04:10PM	Immuneering Announces Inclusion in the Russell 2000® Index (GlobeNewswire) -11.27%
Sep-09-21 06:30AM	Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Sep-02-21 04:05PM	Immuneering to Participate in September Investor Conferences (GlobeNewswire)
Aug-03-21 04:07PM	Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters Option to Purchase Additional Shares (GlobeNewswire) +12.76%
Jul-30-21 02:24PM	Oncology-Focused Biotech Immuneering Jumps To Wall Street With $112M IPO (Benzinga)

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cormorant Asset Management, LP	10% Owner	Apr 01 '24	Sale	2.90	400,000	1,160,181	2,895,273	Apr 03 05:37 PM
Feinberg Peter	Director	Mar 22 '24	Buy	2.55	25,000	63,713	111,766	Mar 25 09:13 AM
Brakewood Harold Eugene	Chief Business Officer	Mar 22 '24	Buy	2.57	3,900	10,015	3,900	Mar 25 09:10 AM
Schall Thomas J.	Director	Mar 22 '24	Buy	2.55	2,900	7,385	2,900	Mar 25 04:03 PM
Morales Mallory	Chief Accounting Officer	Mar 22 '24	Buy	2.55	393	1,000	8,278	Mar 25 09:04 AM
Morales Mallory	Chief Accounting Officer	Mar 21 '24	Buy	2.72	1,107	3,009	7,885	Mar 25 09:04 AM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Mar 20 '24	Buy	2.86	7,000	20,020	345,896	Mar 21 09:06 AM
Neufeld Leah R	CHIEF PEOPLE OFFICER	Mar 20 '24	Buy	2.88	3,818	10,993	10,029	Mar 21 09:11 AM
Feinberg Peter	Director	Mar 19 '24	Buy	2.56	25,000	64,000	86,766	Mar 19 07:04 PM
Zeskind Benjamin J.	PRESIDENT AND CEO	Mar 19 '24	Buy	2.77	20,000	55,326	2,281,852	Mar 19 06:59 PM
BERMAN ANN E	Director	Mar 18 '24	Buy	2.13	57,965	123,436	67,465	Mar 19 07:10 PM
Feinberg Peter	Director	Mar 18 '24	Buy	2.38	50,000	119,058	61,766	Mar 19 07:04 PM
Cormorant Asset Management, LP	10% Owner	Mar 15 '24	Sale	2.14	400,000	856,400	3,295,273	Mar 18 05:59 PM
Cormorant Asset Management, LP	10% Owner	Mar 14 '24	Sale	3.72	509,091	1,892,603	3,695,273	Mar 18 05:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMRX

Immuneering Corp

Upgrade your FINVIZ experience